Dr. Jihad Slim, MD

Medicare patients and services

Medicare patients, 2024

195

Services billed

536

Patients’ average age

69

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 339 payments worth $290,914 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New Jersey →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $430,701 in research payments for these studies, mostly to the institutions running them.

• A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US)
  Theratechnologies Inc.
• A phase 2B multicenter, randomized, open-label study comparing the eff
  Viiv Healthcare Company
• A phase 3B, open label, randomized, standard-of-care control arm, mult
  Viiv Healthcare Company
• Switch to dovato in patients suppressed on biktarvy (sound)
  Viiv Healthcare Company
• A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidne…
  Vertex Pharmaceuticals Incorporated
• A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression
  Merck Sharp & Dohme LLC
• A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
  AbbVie Inc. · Terminated · NCT06032546
• A randomized, double-blind (sponsor unblinded), placebo-controlled, ph
  Viiv Healthcare Company
• A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Tra…
  Gilead Sciences, Inc.
• M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of…
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Infectious Disease clinicians in Newark

• Amany Abu Hanoud, M.D
• Susanne O. Ajao, MD
• David Alland, MD
• Jaspreet Banga
• Maymonah Belal
• Gilda Bontempo, M.D
• Debra Chew, M.D.
• Fabian Dammann, MD